Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
3,4-Dibromo-2-fluoroaniline is a chemical compound primarily characterized as a drug impurity. This molecule is often encountered in the synthesis of pharmaceuticals, where it may arise during the manufacturing process. Its identification and quantification are essential for ensuring the purity and safety of drug products in compliance with regulatory standards. Analytical applications of this compound include use in impurity profiling and quality control testing within the pharmaceutical industry. -
Drug Impurity
Ranitidine impurity 11 is a known impurity associated with Ranitidine. Its presence may impact the pharmaceutical quality and efficacy of formulations containing Ranitidine. This compound is essential for analytical chemistry applications, particularly in the assessment of drug purity and stability in pharmaceutical research. -
Drug Impurity
Clozapine impurity 1 is a known impurity associated with the antipsychotic agent clozapine. This compound serves as a critical reference standard for the analysis and characterization of clozapine formulations. Its identification and quantification are essential in ensuring the quality and safety of pharmaceutical products containing clozapine. Researchers utilize this impurity for method development in stability testing and compliance with regulatory standards. -
Drug Impurity
Ciprofloxacin impurity 8 is a known impurity related to the antibiotic Ciprofloxacin. It may be utilized in analytical chemistry to help in the assessment of drug purity and stability. This compound is essential for research applications focusing on the quality control of pharmaceutical formulations containing Ciprofloxacin. Further studies may explore its potential effects and interactions in biological systems. -
Drug Impurity
Cinakase impurity 13 is a known impurity associated with the drug Cinakase. This compound serves as a critical reference standard for the analysis of drug purity and quality control in pharmaceutical research. It is utilized in various applications related to the assessment of drug formulation integrity and can aid in the development of analytical methodologies to detect impurities during the drug development process. -
Drug Impurity
Levothyroxine impurity 4 is a known impurity of the thyroid hormone replacement therapy, Levothyroxine. This compound can be utilized in analytical studies to assess the purity of Levothyroxine preparations. Its characterization is essential for ensuring the quality and safety of pharmaceutical formulations containing Levothyroxine. -
Drug Impurity
Carvedilol impurity 9 (4'-Benzyloxy carvedilol) is a known impurity of the beta-blocker Carvedilol. This compound is analyzed for its potential effects on drug efficacy and safety profiles during pharmaceutical development. It is relevant for studies assessing the purity of Carvedilol formulations and understanding the implications of impurities in drug performance. -
Drug Impurity
14,15-Dehydro budesonide is a drug impurity with implications in pharmacological research. It serves as a valuable reference standard for analytical studies assessing the purity of budesonide formulations. The presence of this compound can impact the evaluation of drug efficacy and safety, making it essential for quality control in pharmaceutical development. -
Drug Impurity
Terbinafine impurity 9 is a known impurity associated with the antifungal compound Terbinafine. This compound can serve as a critical reference standard for quality control and analytical testing in pharmaceutical development. Its characterization is essential for assessing the purity and compliance of Terbinafine formulations, enabling more accurate evaluations in drug development and safety assessments. -
Drug Impurity
Sertraline impurity 7, also known as rac-cis-3,4-Deschlorosertraline, is a chemical impurity associated with the selective serotonin reuptake inhibitor (SSRI) Sertraline. This compound is significant for research into the safety and efficacy of Sertraline as well as its metabolites. It may be utilized in analytical studies to assess the purity of pharmaceutical formulations and to understand the implications of impurities in pharmacological profiles. -
Drug Impurity
Montelukast impurity 2 ((S)-MK0476) is a characterized impurity of the leukotriene receptor antagonist Montelukast. It serves as a critical reference standard for quality control and stability testing in pharmaceutical formulations. This compound is essential for studies focusing on the synthesis and purification processes related to Montelukast, ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Dabigatran impurity 45 is a chemical impurity associated with the anticoagulant agent Dabigatran. It is primarily utilized as a reference standard for analytical characterization and quality control in pharmaceutical research. This impurity is important for ensuring the safety and efficacy of Dabigatran formulations in drug development and compliance testing. -
Drug Impurity
Dexamethasone impurity 4 is a known impurity associated with Dexamethasone. This compound is primarily used in quality control and analytical chemistry to assess the purity of Dexamethasone formulations. It serves as a reference standard for method validation and helps ensure compliance with regulatory requirements in pharmaceutical development and manufacturing. -
Drug Impurity
Ondansetron impurity 4 is a chemical impurity associated with the pharmaceutical compound Ondansetron. It serves as an important reference standard in the quality control and assessment of drug formulations. This impurity can be utilized in analytical applications to ensure the purity and safety of Ondansetron-based medications, contributing to the understanding of its chemical profile in pharmaceutical research. -
Drug Impurity
Terbinafine impurity 3 is a known impurity of the antifungal agent terbinafine, primarily associated with its synthesis and pharmacological assessment. Its characterization and evaluation are essential for ensuring the purity and quality of terbinafine in pharmaceutical formulations. This impurity can be utilized in compliance studies and to elucidate the metabolic pathways of terbinafine in various biological systems. -
Drug Impurity
Ciprofloxacin impurity 1, also known as Ciprofloxacin impurity C, is a known impurity of the antibiotic Ciprofloxacin. This compound is primarily utilized in pharmaceutical research for the assessment of drug purity and quality control in ciprofloxacin formulations. Its presence in drug samples offers important insights into the synthesis and stability of ciprofloxacin, making it essential for regulatory compliance and safety evaluations in drug development. -
Drug Impurity
Methylprednisolone acetate impurity 7 is a recognized impurity associated with the corticosteroid Methylprednisolone acetate. This compound serves as a critical reference standard in pharmacological and analytical research, particularly in ensuring the purity and quality of pharmaceutical formulations. Its characterization can aid in the assessment of drug stability, efficacy, and safety profiles in various biological systems. -
Drug Impurity
(S)-2-Amino-3-(4-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoic acid serves as a drug impurity relevant to the characterization and quality control of Levothyroxine. This compound can be employed in analytical studies to identify and quantify impurities within pharmaceutical formulations. Its presence may impact the efficacy and safety of Levothyroxine, making it valuable for researchers engaged in drug development and compliance testing. -
Drug Impurity
6-Chloroconazole impurity 17 is a known impurity of the antifungal agent 6-Chloroconazole. Its identification is crucial for quality control and regulatory compliance in pharmaceutical formulations. This compound serves as a reference standard for analytical techniques, aiding in the evaluation of drug purity and stability in chemical research and development. -
Drug Impurity
Domperidone impurity 2 is a known impurity associated with the pharmaceutical compound Domperidone. As a drug impurity, it is critical for ensuring the safety and efficacy of formulations containing Domperidone. Its characterization plays a significant role in quality control during drug development and regulatory assessments. This compound is essential for research focusing on the identification and quantification of impurities in pharmaceutical products. -
Drug Impurity
Carvedilol impurity 10, also known as N-Benzylcarvedilol, is a drug impurity associated with Carvedilol. Its presence in pharmaceutical formulations is significant for studying the safety, efficacy, and quality of the main compound. This impurity is essential for analytical applications, including method development and validation, ensuring compliance with regulatory standards in drug manufacturing. -
Drug Impurity
Citalopram impurity 10 is a drug impurity associated with the selective serotonin reuptake inhibitor Citalopram. This impurity serves as a critical analytical reference standard for pharmaceutical development and quality control, facilitating the assessment of Citalopram's purity and stability. Its presence in formulations underscores the importance of ensuring drug safety and efficacy through rigorous impurity profiling in pharmaceutical research. -
Drug Impurity
Apixaban impurity 15 is a specific impurity associated with the cardiovascular drug Apixaban, a selective factor Xa inhibitor. This compound is essential for quality control and analytical studies in pharmaceutical research and development, particularly in the assessment of drug purity and stability. Researchers utilize this impurity to investigate the degradation products and ensure compliance with regulatory standards. -
Drug Impurity
Buspirone impurity 5, also referred to as Buspirone impurity B, is a known impurity associated with the synthesis of Buspirone. This compound serves as a critical analytical standard for the assessment of drug purity and quality control in pharmaceutical research. Its identification and quantification are essential for ensuring the safety and efficacy of Buspirone formulations. -
Drug Impurity
Telmisartan impurity 12 is a recognized impurity of the antihypertensive agent Telmisartan. Its characterization is important for quality control in pharmaceutical development and formulation. This reagent is utilized in research to ensure the integrity and safety of Telmisartan-based therapies. -
Drug Intermediate
p-SCN-Bn-DOTA(tBu)4 is a derivative of DOTA that acts as a drug intermediate. It serves as a key component in the Gd(III)-DOTA-IAC, a targeted magnetic resonance imaging (MRI) contrast agent designed for the αvβ3 integrin receptor. This compound is valuable in biomedical research for developing specific imaging agents that can enhance the visualization of tumor tissues and facilitate targeted therapies. -
Drug Impurity
Metoprolol impurity 6 is a chemical impurity associated with the synthesis of Metoprolol, a selective beta-1 adrenergic antagonist. This compound can be utilized in pharmaceutical research for the characterization and quantification of impurities in drug formulations. Its analysis is essential for ensuring the safety and efficacy of Metoprolol products in clinical applications. -
Drug Impurity
Olmesartan impurity 3 is a chemical impurity associated with the angiotensin II receptor blocker, Olmesartan. It serves as an important reference standard for quality control and validation in pharmaceutical studies. This reagent is suitable for use in analytical research, including purity assessment and stability testing of drug formulations containing Olmesartan. -
Drug Impurity
Leflunomide impurity 3, a structural isomer of Leflunomide, serves as a drug impurity for quality assessment and regulatory compliance. This compound can be utilized in analytical studies to investigate the stability and purity of Leflunomide formulations. Its presence and characterization are essential for ensuring the safety and efficacy of pharmaceutical products containing Leflunomide. -
Drug Impurity
Sofosbuvir impurity 6 is a known impurity associated with the antiviral drug Sofosbuvir, which targets the hepatitis C virus polymerase. This compound is essential for analytical chemistry studies and serves as a reference standard in pharmaceutical formulations to ensure the quality and efficacy of Sofosbuvir products. Its application is critical in the development and validation of analytical methods for drug purity assessment. -
Drug Impurity
Dacomitinib impurity 16 is a chemical byproduct associated with Dacomitinib, a potent irreversible inhibitor of the epidermal growth factor receptor (EGFR). This impurity can serve as a reference standard in analytical chemistry to ensure the quality and purity of Dacomitinib during drug development. It is useful for researchers engaged in the assessment of pharmaceutical formulations and the development of related compounds. -
Drug Impurity
Afatinib impurity 7, also known as Boc-D-Arg(NO2)-OH, is a recognized impurity associated with the tyrosine kinase inhibitor Afatinib. This compound is primarily used in analytical development and quality control processes to assess the purity of Afatinib formulations. Its characterization is essential for ensuring the integrity and efficacy of pharmaceutical products containing Afatinib. -
Drug Impurity
Duloxetine impurity 8 is a chemical impurity associated with the synthesis of Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI). This compound is primarily used in pharmaceutical research to assess the purity and quality of Duloxetine formulations. Its presence can provide insights into synthetic processes and potential effects on pharmacological activity, making it valuable for drug development and regulatory compliance studies. -
Drug Impurity
Levothyroxine impurity 6 is a characterized impurity associated with Levothyroxine, primarily known for its implications in pharmaceutical quality control. This compound serves as an important reference standard for assessing the purity and stability of Levothyroxine formulations. Its analysis is critical in ensuring compliance with regulatory standards and maintaining the integrity of pharmaceutical products. -
Drug Impurity
Rosuvastatin impurity 33 is a chemical impurity associated with Rosuvastatin, a cholesterol-lowering agent that inhibits HMG-CoA reductase. This impurity is utilized primarily in pharmaceutical research to assess the purity and quality of Rosuvastatin formulations. Its presence and behavior in various formulations aid in the understanding of the drug’s stability and efficacy. -
Drug Impurity
Candesartan impurity 3 is a known impurity of the antihypertensive agent Candesartan. As a drug impurity, it plays a significant role in the assessment of the purity and quality of pharmaceutical formulations containing Candesartan. This reagent is essential for researchers focusing on drug development and validation processes, ensuring compliance with regulatory standards. -
Ciprofloxacin Impurity
N-Nitrosociprofloxacin is an impurity of the fluoroquinolone antibiotic ciprofloxacin. It is of significant interest in chemical research and analytical studies focused on drug quality and safety assessment. Understanding its properties aids in evaluating the stability and degradation pathways of ciprofloxacin in various formulations. -
Drug Impurity
Salmeterol impurity 9 is a known impurity associated with the beta-2 adrenergic agonist Salmeterol. This compound is primarily used in the analysis and quality control of Salmeterol formulations. It serves as an important reference standard for assessing the purity and stability of Salmeterol in pharmaceutical research and development. -
Promethazine Impurity
Isopromethazine hydrochloride is an impurity associated with Promethazine, a well-known N-substituted phenothiazine. This compound functions primarily as an H1-receptor antagonist, exhibiting antihistaminic properties. Isopromethazine hydrochloride is relevant for quality control and analytical studies in pharmaceutical formulations of Promethazine, aiding in the assessment of purity and consistency in drug manufacturing. -
Drug Impurity
Acyclovir impurity 8 is a structural impurity related to Acyclovir, an antiviral medication primarily used in the treatment of herpes simplex virus infections. This impurity is relevant for analytical and quality control studies in pharmaceutical development. Understanding the chemical profile and behavior of drug impurities is crucial for ensuring the safety and efficacy of antiviral therapies. -
Drug Impurity
Terbinafine impurity 12 is a chemical impurity associated with Terbinafine, an antifungal agent. This compound is primarily utilized in quality control and analytical assessments of Terbinafine formulations. Its identification is crucial for ensuring the purity and efficacy of pharmaceutical products containing Terbinafine. -
Drug Impurity
Rivastigmine impurity 6, also known as Rivastigmine N-oxide, is a chemical impurity associated with the drug Rivastigmine. This compound plays a significant role in quality control and characterization of pharmaceutical formulations. Its analytical assessment is essential for ensuring the purity and efficacy of Rivastigmine-based therapies in research and development settings. Rivastigmine impurity 6 is useful for various investigations into drug metabolism and safety. -
Drug Impurity
Salbutamol impurity 4 is a known impurity of the bronchodilator Salbutamol, primarily utilized in pharmaceutical analysis. This compound serves as a critical reference standard for assessing the purity and quality of Salbutamol formulations. Its presence and quantification are essential in ensuring compliance with regulatory standards in drug development and quality control processes. -
Drug Impurity
Fluphenazine impurity 5 is a minor impurity associated with the antipsychotic agent Fluphenazine. This compound serves as a critical standard for quality control and analytical validation in the production of pharmaceutical formulations containing Fluphenazine. Its characterization is essential for ensuring the safety, efficacy, and compliance of drug products in pharmaceutical research and development. -
Drug Impurity
Amodiaquine impurity 4 is a chemical impurity associated with the synthesis of Amodiaquine. Its characterization is essential for ensuring the purity and safety of pharmaceutical formulations. This impurity can be used in research applications focused on drug metabolism and pharmacokinetics, as well as regulatory compliance for quality control in manufacturing processes. -
Drug Impurity
1,11b-Dedihydrotetrabenazine is classified as a drug impurity. This compound serves as a critical reference standard in the analysis of tetrabenazine formulations, facilitating the assessment of quality and compliance in pharmaceutical development. It is essential for researchers evaluating the safety and efficacy of related therapeutic agents. -
Drug Impurity
Telmisartan impurity 2 is a chemical impurity associated with Telmisartan, primarily identified as a drug impurity. This compound is utilized in pharmaceutical research to ensure the purity and quality of Telmisartan formulations. Its presence and characterization are essential for regulatory compliance and safety evaluations in drug development processes. -
Drug Impurity
Tenofovir Impurity 6 is a chemical impurity associated with the antiviral drug Tenofovir, which targets the reverse transcriptase enzyme. This impurity may be relevant for analytical studies, quality control processes, and method development in the pharmaceutical research of Tenofovir and its formulations. Understanding the profile of this impurity is essential for ensuring the safety and efficacy of drug products. -
Drug Impurity
Citalopram impurity 4, chemically known as 3-Oxocitalopram, functions as a drug impurity associated with the antidepressant Citalopram. Its presence is important for stability studies and the evaluation of pharmaceutical formulations. This compound is significant in research related to drug development and quality control, enabling the assessment of the purity and safety of Citalopram products. -
Drug Intermediate
Levetiracetam impurity 9 is identified as a drug intermediate in the synthesis of Levetiracetam. This chemical is primarily utilized for the characterization and quality control of Levetiracetam formulations. Its presence serves as a reference standard in analytical assays and helps ensure the purity of pharmaceutical products.
